Pulmonary Hypertension Due to Left Heart Disease: an Update

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2019 May 29

PMID 31134443

Citations 7

Authors

Mandar A Aras

Mitchell A Psotka

Teresa De Marco

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Pulmonary hypertension (PH) frequently complicates heart failure and portends a worse prognosis. This review will summarize and discuss recent updates in the classification and management of patients with PH due to left heart disease.

Recent Findings: Careful hemodynamic assessment is critical to the classification of patients with PH and heart failure. Two hemodynamic subgroups of PH in heart failure patients have been described: isolated post-capillary pulmonary hypertension and combined post- and precapillary pulmonary hypertension. The cornerstone in management of PH due to left heart disease is the treatment of the underlying left heart pathology; however, ongoing trials have been designed to test pulmonary vasodilators in this cohort. PH-specific therapies have not demonstrated a benefit in patients with pulmonary hypertension due to left heart disease. Understanding the distinct pathobiology of each hemodynamic subgroup may lead to the development of useful biomarkers and effective targeted therapies.

Citing Articles

Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension.

Helleberg S, Engel A, Ahmed S, Ahmed A, Radegran G Am Heart J Plus. 2024; 20:100190.

PMID: 38560419 PMC: 10978361. DOI: 10.1016/j.ahjo.2022.100190.

Progress in Pulmonary Vein Stenosis: Lessons from Success in Treating Pulmonary Arterial Hypertension.

Jenkins K, Fineman J Children (Basel). 2022; 9(6).

PMID: 35740736 PMC: 9222029. DOI: 10.3390/children9060799.

regulates inflammasome-mediated hypertensive cardiac inflammation and fibrosis .

Chen H, Qiao H, Zhao Q, Wei F Bioengineered. 2022; 13(3):4658-4673.

PMID: 35148667 PMC: 8973706. DOI: 10.1080/21655979.2021.2024956.

Unmasking of left heart dilation following treatment for precapillary pulmonary hypertension.

Rogg S, Thomason J, Boyd N Can Vet J. 2021; 62(11):1177-1180.

PMID: 34728842 PMC: 8543657.

Pulmonary vasodilator use in continuous-flow left ventricular assist device management.

Pirlamarla P, Rame E, Hoopes C, Rajapreyar I Ann Transl Med. 2021; 9(6):522.

PMID: 33850919 PMC: 8039680. DOI: 10.21037/atm-20-4710.

References

Mehra M, Canter C, Hannan M, Semigran M, Uber P, Baran D . The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016; 35(1):1-23. DOI: 10.1016/j.healun.2015.10.023. View

Assad T, Maron B, Robbins I, Xu M, Huang S, Harrell F . Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiol. 2017; 2(12):1361-1368. PMC: 5814998. DOI: 10.1001/jamacardio.2017.3882. View

DAscenzo F, Conrotto F, Salizzoni S, Rossi M, Nijhoff F, Gasparetto V . Incidence, predictors, and impact on prognosis of systolic pulmonary artery pressure and its improvement after transcatheter aortic valve implantation: a multicenter registry. J Invasive Cardiol. 2015; 27(2):114-9. View

Fang J, DeMarco T, Givertz M, Borlaug B, Lewis G, Rame J . World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012; 31(9):913-33. DOI: 10.1016/j.healun.2012.06.002. View

Fayyaz A, Edwards W, Maleszewski J, Konik E, DuBrock H, Borlaug B . Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation. 2017; 137(17):1796-1810. PMC: 5915920. DOI: 10.1161/CIRCULATIONAHA.117.031608. View

Reddy Y, Carter R, Obokata M, Redfield M, Borlaug B . A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018; 138(9):861-870. PMC: 6202181. DOI: 10.1161/CIRCULATIONAHA.118.034646. View

Naeije R, Gerges M, Vachiery J, Caravita S, Gerges C, Lang I . Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure. Circ Heart Fail. 2017; 10(9). DOI: 10.1161/CIRCHEARTFAILURE.117.004082. View

Lewis G, Ngo D, Hemnes A, Farrell L, Domos C, Pappagianopoulos P . Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll Cardiol. 2016; 67(2):174-189. PMC: 4962613. DOI: 10.1016/j.jacc.2015.10.072. View

Andersen M, Olson T, Melenovsky V, Kane G, Borlaug B . Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail. 2014; 8(1):41-8. DOI: 10.1161/CIRCHEARTFAILURE.114.001731. View

10.

Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S . Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2013; 145(5):1064-1070. DOI: 10.1378/chest.13-1510. View

11.

Masri S, Tedford R, Colvin M, Leary P, Cogswell R . Pulmonary Arterial Compliance Improves Rapidly After Left Ventricular Assist Device Implantation. ASAIO J. 2016; 63(2):139-143. DOI: 10.1097/MAT.0000000000000467. View

12.

Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L . Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg. 2007; 133(3):689-95. DOI: 10.1016/j.jtcvs.2006.08.104. View

13.

Arkles J, Opotowsky A, Ojeda J, Rogers F, Liu T, Prassana V . Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2010; 183(2):268-76. DOI: 10.1164/rccm.201004-0601OC. View

14.

Dragu R, Rispler S, Habib M, Sholy H, Hammerman H, Galie N . Pulmonary arterial capacitance in patients with heart failure and reactive pulmonary hypertension. Eur J Heart Fail. 2014; 17(1):74-80. DOI: 10.1002/ejhf.192. View

15.

DAlto M, Romeo E, Argiento P, Pavelescu A, Melot C, DAndrea A . Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. J Am Soc Echocardiogr. 2014; 28(1):108-15. DOI: 10.1016/j.echo.2014.09.004. View

16.

Dupont M, Mullens W, Skouri H, Abrahams Z, Wu Y, Taylor D . Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail. 2012; 5(6):778-85. PMC: 3538355. DOI: 10.1161/CIRCHEARTFAILURE.112.968511. View

17.

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

18.

Meoli D, Ru Su Y, Brittain E, Robbins I, Hemnes A, Monahan K . The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension. Pulm Circ. 2017; 8(1):2045893217745019. PMC: 5764145. DOI: 10.1177/2045893217745019. View

19.

Luo N, Craig D, Ilkayeva O, Muehlbauer M, Kraus W, Newgard C . Plasma acylcarnitines are associated with pulmonary hypertension. Pulm Circ. 2017; 7(1):211-218. PMC: 5448546. DOI: 10.1086/690554. View

20.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View